Monday, October 6


Monday, October 6

(The presenters of gray titles did not allow the online appearance of their lectures )


1. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-12.00 – Monday, October 6

Chair Persons: S. Smith, M.R.J. Kohonen-Corish


2. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION

ROOM A, 13.00-16.15 – Monday, October 6

Chair Persons: D.W. Felsher, A. Seth

  • Modeling and predicting consequences of therapeutic oncogene inactivation. D.W. Felsher (Stanford, CA, USA) (40’)
  • Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. R.P. Charles, J. Silva, G. Iezza, W.A. Phillips, M. McMahon (San Francisco, CA, USA; Melbourne, Australia; Bern, Switzerland) (30’)
  • Post-translational regulation of COX2 activity by FYN in prostate cancer cells. A. Sorokin (Milwaukee, WI, USA) (25’)
  • Tumor suppressor protein IGFBP7 blocks phosphatidylinositol-3-kinase-AKT signaling by binding to the IGF-1 receptor. Y. Amemiya, T. Benatar, V. Evdokimova, W. Yang, A. Seth (Toronto,ON, Canada) (15’) 
  • Steroid receptor co-activators and oestrogen receptor beta-1 isoform as survival biomarkers in malignant pleural mesothelioma. C.J. Jennings, B. Murer, A. O’Grady, B.J. Harvey, E.W. Kay, W. Thomas (Dublin, Ireland; Mestre, Italy) (30’)
  • From bench to bed, from single gene to multiplex analysis, and challenges and accomplishments in fighting lung cancer. S. Long, G. Otterson, D. Carbone, M. Villalona, Y.Tang, K. Shilo, W. Zhao (Columbus, OH, USA) (15’)
  • Right-sided tumours and related unexplained iron-deficiency anaemia(IDA) are associated with BRAF V600E mutation in colorectal cancer patients. M. Sideris, K. Adams, J. Moorhead, S. Diaz-Cano, S. Papagrigoriadis (London, UK) (10’)

3. EPIGENETICS

ROOM A, 16.30-19.00 – Monday, October 6

Chair Persons: W. Engström, G. Broich


4. NEW ANTICANCER AGENTS

ROOM B, 08.00-10.00 – Monday, October 6

Chair Persons: L. Amaral, S. Shany


5. NEW ANTICANCER AGENTS

ROOM B, 10.00-12.00 Monday, October 6

Chair Persons: H. Maeda, D.L. Vesely


6. DRUG DELIVERY
Special Symposium Organized by D. Vetvicka

ROOM B, 13.00-17.30 – Monday, October 6

Chair Person: D. Vetvicka

  • Nanomedicine for cancer selective drug delivery; Advantages of the EPR effect and pitfalls. H. Maeda, H. Nakamura, J. Fang (Kumamoto, Japan) (30′)
  • Polymer-drug conjugates for targeted tumor therapy. T. Etrych, P. Chytil, E. Koziolová, M. Šírová, S. Hoffman, T. Müller, K. Mäder, B. Ríhová, K. Ulbrich (Prague, Czech Republic) (30′)
  • Bionanotechnology and novel targeted drug delivery systems. A. Syed (Edinburgh, UK) (30′)
  • Ultrasound-responsive systems for targeted cancer therapy. A.P. McHale, K. Curtis, N. Nomikou, B. Callan, J.F. Callan (Coleraine, Northern Ireland; London, UK) (30′)
  • Experimental topical photodynamic therapy of cancer with liposomal hydroxy-aluminium phthalocyanine. D. Vetvicka, M. Zadinova, M. Nekvasil, P. Jezek, J. Rakusan, M. Karaskova, J. Kralova, V. Kral, P. Pouckova (Prague; Rybitvi, Czech Republic) (30′)
  • Tumor regression after intravenous administration of novel tumour-targeted nanomedicines. C. Dufès (Glasgow, UK) (30′)
  • The Atomic Force Microscopy (AFM) in nanomedicine. D.A. Lamprou (Glasgow, Scotland, UK) (30′)
  • Polymer donors of nitric oxide for enhanced accumulation of anticancer agent in the solid tumor microenvironment. M. Studenovský, M. Šírová, B. Ríhová, K. Ulbrich (Prague, Czech Republic) (15′)

7. EXPERIMENTAL CHEMOTHERAPY

ROOM B, 17.45-19.30 – Monday, October 6

Chair Persons: L. Helson, S. Palakurthi, V. Treska

  • Oral formulation of a liposome breakdown product mitigates intravenous Moxifloxacin induced QTc prolongation in vivo. L. Helson, G. Shopp, A. Bouchard, M. Majeed, D. Salvail, W. Shaw (Boulder, CO,; Winsdor, NJ, USA; Sherbrooke, QC, Canada) (30′)
  • Nano polymer-cisplatin complexes for chemotherapy of ovarian cancer. S. Palakurthi, V.K. Yellepeddi (Kingsville, TX, USA) (30′)
  • The promise of sonodynamic therapy: using ultrasonic irradiation and chemotherapeutic agents as a treatment modality. M. Trendowski (Syracuse, NY, USA) (15′)
  • Portal vein embolisation with the application of haematopoietic stem cells in patients with primarily non-resectable colorectal liver metastases. V. Treska, V. Liska, J. Fichtl, D. Lysak, H. Mirka, J. Bruha, P. Duras (Pilsen, Czech Republic) (15′)

8. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM C, 08.00-09.50 – Monday, October 6

Chair Persons: S. Arbak, T. Dalianis, T. Theophanides


9. CLINICAL CHEMOTHERAPY

ROOM C, 10.00-12.00 – Monday, October 6

Chair Persons: F. Muggia, R. Klapdor


10. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM C, 13.00-15.30 – Monday, October 6

Chair Persons: Y. Keisari, S. Kumar


11. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM C, 15.45-18.00 – Monday, October 6

Chair Persons: D. Characiejus, F. Guadagni


12. TARGETING THE TUMOUR MICROENVIRONMENT (A)
Special Symposium Organized by I.P. Witz and Y. Keisari

ROOM D, 8.00-12.00 – Monday, October 6

Chair Persons: I.P. Witz, Y. Keisari


13. TARGETING THE TUMOUR MICROENVIRONMENT (B)
Special Symposium Organized by D. D. Spyropoulos and G. Sica

ROOM D, 13.00-17.00 – Monday, October 6

Chair Persons: D. D. Spyropoulos, G. Sica


14. CIRCULATING TUMOR CELLS
Special Symposium Organized by M.Rigaud

ROOM D, 17.15-19.35 – Monday, October 6

Chair Persons: M. Rigaud, S.S. Martin


15. CARCINOGENESIS; VIRAL ONCOGENESIS

ROOM E, 08.00-09.30 – Monday, October 6

Chair Persons: W. Engström, A.R. Young

  • Photoprotection by sunscreens and skin cancer. A.R. Young (London, UK) (30’)
  • The HALIFAX project – an attempt to assess the carcinogenicpotential of low dose exposures to chemical mixtures in the environment. W. Engström, T. Hultman, L. Lowe (Uppsala, Sweden; Nova Scotia, Canada) (15’)
  • A metal exposured cohort study in the largest metal workers population in the world. Y. Bai (Lanzhou, Gansu, PR China) (15’)

16. ALTERNATIVE AND COMPLEMENTARY MEDICINE IN CANCER TREATMENT
Special Symposium Organized by S. Pathak

ROOM E, 9.40-12.00 – Monday, October 6

Chair Persons: B.B. Aggarwal, S. Pathak


17. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM E, 13.00-16.00 – Monday, October 6

Chair Persons: T. Efferth, J. Molnar


18. THE SUGAR CODE IN TUMOR BIOLOGY/PATHOLOGY: PRINCIPLES AND EXAMPLES
Special Symposium Organized by H.J. Gabius

ROOM E, 16.00-19.00 – Monday, October 6

Chair Persons: H.J. Gabius, K. Kayser, J. Kopitz, K. Smetana Jr


19. CANCER GENOMICS. MICROARRAY TECHNOLOGY

ROOM F, 8.00-10.00 – Monday, October 6

Chair Persons: D. Anderson, D.-T. Bau


20. CANCER GENOMICS. MICROARRAY TECHNOLOGY

ROOM F, 10.00-12.30 – Monday, October 6

Chair Persons: R. Narayanan, C. Nicolini


21. GENOMIC INSTABILITY AND CANCER (DNA REPAIR)
Special Symposium Organized by A.A. Wani

ROOM F, 13.00-19.30 – Monday, October 6

Chair Persons: A.A. Wani, R.M. Snapka

  • Chromatin structure and ionizing radiation signaling. T.K. Pandita (Houston, TX, USA) (40’)
  • Ubiquitination and deubiquitination of DNA repair factors : Modulation by modification. J. He, Q. Zhu, G. Wani, N. Sharma, C. Han, J. Qian, K. Pentz, Q. Wang and A.A. Wani (Columbus, OH,USA) (30’)
  • DNA damage-induced regulation of base excision repair protein stability and ARTD1 activation. R.W. Sobol (Pittsburg, PA, USA) (30’)
  • Regulatory mechanisms of transcription-coupled DNA repair. S. Malik, P. Chaurasia, R. Sen, S. Lahudkar, G. Durairaj, B. Uprety, S. R. Bhaumik (Carbondale, IL, USA) (40’)
  • Single stranded DNA binding protein 1 recruits TERT to telomeres. R.K. Pandita, D. Udayakumar, C.R. Hunt, N. Horikoshi, T.K. Pandita (Houston, TX, USA) (40’)
  • Thymoquinone inhibition of autophagy causes growth inhibition and caspase-independent death of glioblastoma cells. R.M. Snapka, I.O. Racoma, W.H. Meisen, Q.-E. Wang, B. Kaur, A.A. Wani (Ohio,USA) (30’)
  • ROS mechanisms mediate the inhibition of oral cancer by avocado extract. H. Ding, B. Casto, Y. Deng, K. Grill, W. Duan, N. Zhang, S. Cole, K. La Perle, X. Pan, A.D. Kinghom, S.M. D’Ambrosio (Columbus , OH, USA) (25’)
  • DNA damage responses in ovarian cancer stem cells. A. K. Srivastava, C. Han, R. Zhao, T. Cui, Q.-E. Wang (Columbus , OH, USA) (30’)
  • Oxidative genome damage repair deficiency in a human DNA glycosylase NEIL2 variant: Potential linkage to lung cancer susceptibility. T. Hazra (Galveston, TX, USA) (30’)